BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 20551460)

  • 1. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
    Reinisch W; Angelberger S; Petritsch W; Shonova O; Lukas M; Bar-Meir S; Teml A; Schaeffeler E; Schwab M; Dilger K; Greinwald R; Mueller R; Stange EF; Herrlinger KR;
    Gut; 2010 Jun; 59(6):752-9. PubMed ID: 20551460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn's disease].
    Nos P; Hinojosa J; Aguilera V; Molés JR; Pastor M; Ponce J; Berenguer J
    Gastroenterol Hepatol; 2000 Oct; 23(8):374-8. PubMed ID: 11227650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.
    Savarino E; Bodini G; Dulbecco P; Assandri L; Bruzzone L; Mazza F; Frigo AC; Fazio V; Marabotto E; Savarino V
    Am J Gastroenterol; 2013 Nov; 108(11):1731-42. PubMed ID: 24019080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease.
    Ford AC
    Gut; 2010 Dec; 59(12):1731-2. PubMed ID: 20729230
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease-the authors' response.
    Reinisch W; Stange EF;
    Gut; 2011 May; 60(5):739-40. PubMed ID: 21363886
    [No Abstract]   [Full Text] [Related]  

  • 7. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
    Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
    Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial.
    Cezard JP; Munck A; Mouterde O; Morali A; Lenaerts C; Lachaux A; Turck D; Schmitz J; Maurage C; Girardet JP; Belli D; Lamireau T; Sarles J; Chouraqui JP; Descos B; Dabadi A; Meyer M; Olives JP; Mary JY
    Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):31-40. PubMed ID: 19118966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for the prevention of postoperative recurrence of Crohn's disease.
    Yamamoto T; Watanabe T
    Colorectal Dis; 2013 Dec; 15(12):1471-80. PubMed ID: 23809911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
    Dotan I; Rachmilewitz D; Schreiber S; Eliakim R; van der Woude CJ; Kornbluth A; Buchman AL; Bar-Meir S; Bokemeyer B; Goldin E; Maaser C; Mahadevan U; Seidler U; Hoffman JC; Homoky D; Plasse T; Powers B; Rutgeerts P; Hommes D;
    Gut; 2010 Jun; 59(6):760-6. PubMed ID: 20551461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.
    Reinisch W; Panés J; Lémann M; Schreiber S; Feagan B; Schmidt S; Sturniolo GC; Mikhailova T; Alexeeva O; Sanna L; Haas T; Korom S; Mayer H
    Am J Gastroenterol; 2008 Sep; 103(9):2284-92. PubMed ID: 18671816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
    Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study.
    Armuzzi A; Felice C; Papa A; Marzo M; Pugliese D; Andrisani G; Federico F; De Vitis I; Rapaccini GL; Guidi L
    J Crohns Colitis; 2013 Dec; 7(12):e623-9. PubMed ID: 23810678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Colombel JF; Lémann M; Cassagnou M; Bouhnik Y; Duclos B; Dupas JL; Notteghem B; Mary JY
    Am J Gastroenterol; 1999 Mar; 94(3):674-8. PubMed ID: 10086650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of mesalazine for subclinical post-surgical endoscopic recurrence of Crohn's disease despite preventive thiopurine therapy: A case-control study.
    Zabana Y; Mañosa M; Cabré E; Bernal I; Marín L; Lorenzo-Zúñiga V; Moreno V; Boix J; Domènech E
    J Gastroenterol Hepatol; 2014; 29(7):1413-7. PubMed ID: 24627958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Postoperative recurrence of Crohn's disease, and its prevention].
    Lakatos L; Lakatos PL
    Orv Hetil; 2010 May; 151(21):870-7. PubMed ID: 20462847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study.
    Yamamoto T; Umegae S; Matsumoto K
    Inflamm Bowel Dis; 2009 Oct; 15(10):1460-6. PubMed ID: 19266566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.
    Marteau P; Lémann M; Seksik P; Laharie D; Colombel JF; Bouhnik Y; Cadiot G; Soulé JC; Bourreille A; Metman E; Lerebours E; Carbonnel F; Dupas JL; Veyrac M; Coffin B; Moreau J; Abitbol V; Blum-Sperisen S; Mary JY
    Gut; 2006 Jun; 55(6):842-7. PubMed ID: 16377775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine.
    Tang T; Targan SR; Li ZS; Xu C; Byers VS; Sandborn WJ
    Aliment Pharmacol Ther; 2011 Jan; 33(2):194-202. PubMed ID: 21114791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.